Market Mover | ResMed Shares Rise Nearly 6% on Profit Beat
Market Mover | ResMed Shares Rise Nearly 6% on Profit Beat
Gross Shares of $ResMed Inc (RMD.AU)$ rose 5.81% to A$37.69 on Friday, following the release of ResMed's first-quarter results for the fiscal year 2025. The medical equipment manufacturer not only met but exceeded Wall Street's estimates for quarterly profit.
股票$ResMed Inc (RMD.AU)$ 週五，隨着瑞思邁發佈2025財年第一季度業績，股價上漲5.81%至A$37.69。這家醫療設備製造商不僅達到了華爾街對季度利潤的預期，而且超出了。
First Quarter 2025 Highlights
2025財年第一季度亮點
Revenue increased by 11% yoy, from $1.1 billion to $1.2 billion.
Gross margin improved 420 bps yoy, from from 54.4% to 58.6%.
Income from operations increased 34% yoy, from $289 million to $387.3 million.
Diluted earnings per share grew 42% from $1.49 to $2.11.
營業收入同比增長11%，從$11億增至$12億。
毛利率同比增長420個點子，從54.4%提高至58.6%。
營運利潤同比增長34%，從$28900萬增至$38730萬。
每股攤薄收益增長42%，從$1.49增至$2.11。
The robust revenue growth in the quarter is fueled by higher demand for its sleep devices and masks portfolio, along with a surge in its residential care software business. ResMed's improved gross margin is credited to enhanced manufacturing efficiency, reduced component costs, and higher average selling prices. This month, ResMed launched its '2030 strategy', aiming to empower over 500 million individuals to reach their full health potential by 2030.
本季度營業收入強勁增長，來自對其睡眠設備和口罩組合的更高需求，以及住宅護理軟件業務的激增。瑞思邁改善的毛利率歸功於增強的製造效率，降低的零部件成本和更高的平均銷售價格。本月，瑞思邁推出了其「2030年戰略」，旨在到2030年賦予超過50000萬個體達到其全面健康潛力。
According to the Chairman and CEO of ResMed,
根據瑞思邁的董事長兼首席執行官，
"Our first-quarter fiscal year 2025 results reflect ongoing momentum and strong execution across all areas of our business. As we celebrate 35 years of growth and innovation, our recently launched 2030 strategy will further enable us to transform sleep health, breathing health, and healthcare technology at home. "
「我們2025財年第一季度的業績反映了持續的勢頭和在業務的所有領域的強勁執行。在慶祝成立35週年的同時，我們最近推出的2030戰略將進一步使我們能夠在家中改變睡眠健康、呼吸健康和醫療科技。」
Sources: Reuters, ResMed
來源：路透社，瑞思邁
